Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Leukemia. 2020 Nov;34(11):3047-3049. doi: 10.1038/s41375-020-01030-2. Epub 2020 Aug 27.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / blood*
  • Betacoronavirus / immunology*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / blood
  • Coronavirus Infections / complications
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / virology
  • Coronavirus Nucleocapsid Proteins
  • Female
  • Humans
  • Immunity, Cellular
  • Immunoglobulin G / blood*
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / virology
  • Male
  • Middle Aged
  • Nucleocapsid Proteins / immunology
  • Nucleocapsid Proteins / metabolism
  • Pandemics
  • Phosphoproteins
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / virology
  • Protein Binding
  • RNA, Viral / genetics
  • RNA, Viral / immunology
  • SARS-CoV-2
  • Severity of Illness Index

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Coronavirus Nucleocapsid Proteins
  • Immunoglobulin G
  • Nucleocapsid Proteins
  • Phosphoproteins
  • RNA, Viral
  • nucleocapsid phosphoprotein, SARS-CoV-2